XRO:ASXXero Limited Analysis
Data as of 2026-05-29 - not real-time
A$75.17
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Xero's FY26 revenue surged 31% to A$2.75bn, driving a 40% YoY growth rate. Gross margin remains robust at ~84%, but operating margin is modest at ~11% and net profit margin slipped to 6% due to integration costs from the Melio acquisition. The balance sheet shows a high cash position of A$1.93bn offset by comparable debt, yielding a debt‑to‑equity of about 39%. Forward earnings per share are projected at A$2.00, translating to a forward P/E of 37.7, well below the industry average of 41.8. However, the current market price of A$75.17 sits far above the DCF‑derived fair value of A$44.9, implying a ~74% upside/downside gap. Technicals are mixed: the 20‑day SMA (79.33) lies above price, the MACD histogram is negative and the RSI at 42 suggests neither overbought nor oversold conditions. Volatility is elevated at 44% over the past 30 days, while beta of 0.66 points to lower systematic risk. Recent headlines note a 4.7% share drop amid investor disappointment, yet also highlight an 8% rally later in the week, reflecting short‑term sentiment swings. The company’s expansion into the U.S. market and AI‑driven offerings such as Syft bolster its growth narrative. No dividend is paid, making the stock a pure growth play. The sector—technology‑software—carries medium risk, with regulatory exposure to data‑privacy and tax compliance. Geographic diversification across ANZ, UK and the U.S. moderates location‑specific risk, though currency exposure remains medium. Liquidity appears solid with stable volumes and a market cap of A$13 bn. In sum, while fundamentals are strong, the current price premium and bearish short‑term signals warrant a cautious stance.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD histogram indicating downward momentum
- Current price above 20‑day SMA suggesting limited upside
- High short‑term volatility and recent share price swings
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Strong revenue growth of ~40% YoY
- Forward earnings upside with projected EPS of A$2.00
- Expansion into U.S. market and AI‑driven product suite
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Robust gross margins and solid cash generation
- Current market price significantly above DCF fair value
- Competitive SaaS landscape and ongoing integration costs
Key Metrics & Analysis
Financial Health
Revenue Growth40.80%
Profit Margin6.08%
P/E Ratio37.7
ROE4.41%
ROA3.38%
Debt/Equity39.33
P/B Ratio3.2
Op. Cash FlowA$933.1M
Free Cash FlowA$221.1M
Industry P/E41.8
Technical Analysis
TrendNeutral
RSI42.0
SupportA$72.69
ResistanceA$87.00
MA 20A$79.33
MA 50A$78.06
MA 200A$112.88
MACDBearish
VolumeStable
Fear & Greed Index93.89
Valuation
Fair ValueA$44.86
Target PriceA$131.27
Upside/Downside74.63%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.66
Volatility43.72%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.